publication . Article . 2017

Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance

Oroma Nwanodi; Helen Salisbury; Curtis Bay;
Open Access English
  • Published: 01 Nov 2017 Journal: Healthcare, volume 5, issue 4 (issn: 2227-9032, eissn: 2227-9032, Copyright policy)
  • Publisher: MDPI
Abstract
Human papilloma virus (HPV) vaccine was developed to reduce HPV-attributable cancers, external genital warts (EGW), and recurrent respiratory papillomatosis. Adolescent HPV vaccination series completion rates are less than 40% in the United States of America, but up to 80% in Australia and the United Kingdom. Population-based herd immunity requires 80% or greater vaccination series completion rates. Pro-vaccination counseling facilitates increased vaccination rates. Multimodal counseling interventions may increase HPV vaccination series non-completers’ HPV-attributable disease knowledge and HPV-attributable disease prophylaxis (vaccination) acceptance over a bri...
Subjects
mesheuropmc: virus diseasesfemale genital diseases and pregnancy complications
free text keywords: HPV knowledge, HPV vaccination acceptance, human papilloma virus (HPV), counseling, HPV-attributable diseases, Medicine, HPV vaccination, cervical cancer, Article, HPV counseling, R, HPV prophylaxis
Related Organizations
53 references, page 1 of 4

HPV and Cancer. How Many Cancers Are Linked with HPV Each Year?.

Williams, W.W., Lu, P.J., O’Halloran, A., Kim, D.K., Grohskopf, L.A., Pilishvili, T., Skoff, T.H., Nelson, N.P., Harpaz, R., Markowitz, L.E.. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR. 2017; 66: 1-28 [OpenAIRE] [PubMed] [DOI]

Giuliano, A.R., Lu, B., Nielson, C.M., Flores, R., Papenfuss, M.R., Lee, J.H., Abrahamsen, M., Harris, R.B.. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. JID. 2008; 198: 827-835 [PubMed] [DOI]

Forman, D., de Martel, C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M.. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30: F12-F23 [OpenAIRE] [PubMed] [DOI]

Yanofsky, V.R., Patel, R.V., Goldenberg, G.. Genital warts. A comprehensive review. J. Clin. Aesthet. Dermatol.. 2012; 5: 25-36 [OpenAIRE] [PubMed]

Armstrong, L.R., Preston, E.J.D., Reichert, M., Phillips, D.L., Nisenbaum, R., Todd, N.W., Jacobs, I.N., Inglis, A.F., Manning, S.C., Reeves, W.C.. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis.. 2000; 31: 107-109 [PubMed] [DOI]

Chirillă, M., Bolboacă, S.D.. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur. Arch. Otorhinolaryngol.. 2013 [PubMed] [DOI]

Giuliano, A.R., Harris, R., Sedjo, R.L., Baldwin, S., Roe, D., Papenfuss, M.R., Abrahamsen, M., Inserra, P., Olvera, S., Hatch, K.. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The young women’s health study. JID. 2002; 186: 462-469 [PubMed] [DOI]

Charlton, B.M., Reisner, S.L., Agénor, M., Gordon, A.R., Sarda, V., Austin, S.B.. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health. 2017; 4: 202-209 [OpenAIRE] [PubMed] [DOI]

Raymakers, A.J., Sadatsafavi, M., Marra, F., Marra, C.A.. Economic and humanistic burden of external genital warts. Pharmacoeconomics. 2012; 30: 1-16 [PubMed] [DOI]

Van de Velde, N., Boily, M.C., Drolet, M., Franco, E.L., Mayrand, M.H., Kliewer, E.V., Kliewer, E.V., Coutlée, F., Laprise, J.F., Malagón, T.. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: A model-based analysis. J. Natl. Cancer Inst.. 2012; 104: 1712-1723 [OpenAIRE] [PubMed] [DOI]

Schobert, D., Remy, V., Schoeffski, O.. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ. Rev.. 2012; 2: 19 [OpenAIRE] [PubMed] [DOI]

Héquet, D., Rouzier, R.. Determinants of geographic inequalities in HPV vaccination in the most populated region of France. PLoS ONE. 2017; 12 [OpenAIRE] [PubMed] [DOI]

Fregnani, J.H., Carvalho, A.L., Eluf-Neto, J., Ribeiro, K.d.C.B., Kuil, L.d.M., da Silva, T.A., Rodrigues, S.L., Mauad, E.C., Longatto-Filho, A., Villa, L.L.. A school-based human papillomavirus vaccination program in Barretos, Brazil: Final results of a demonstrative study. PLoS ONE. 2013; 8 [OpenAIRE] [PubMed] [DOI]

Hayashi, Y., Shimizu, Y., Netsu, S., Hanley, S., Konno, R.. High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan. Vaccine. 2012; 30: 5547-5550 [PubMed] [DOI]

53 references, page 1 of 4
Abstract
Human papilloma virus (HPV) vaccine was developed to reduce HPV-attributable cancers, external genital warts (EGW), and recurrent respiratory papillomatosis. Adolescent HPV vaccination series completion rates are less than 40% in the United States of America, but up to 80% in Australia and the United Kingdom. Population-based herd immunity requires 80% or greater vaccination series completion rates. Pro-vaccination counseling facilitates increased vaccination rates. Multimodal counseling interventions may increase HPV vaccination series non-completers’ HPV-attributable disease knowledge and HPV-attributable disease prophylaxis (vaccination) acceptance over a bri...
Subjects
mesheuropmc: virus diseasesfemale genital diseases and pregnancy complications
free text keywords: HPV knowledge, HPV vaccination acceptance, human papilloma virus (HPV), counseling, HPV-attributable diseases, Medicine, HPV vaccination, cervical cancer, Article, HPV counseling, R, HPV prophylaxis
Related Organizations
53 references, page 1 of 4

HPV and Cancer. How Many Cancers Are Linked with HPV Each Year?.

Williams, W.W., Lu, P.J., O’Halloran, A., Kim, D.K., Grohskopf, L.A., Pilishvili, T., Skoff, T.H., Nelson, N.P., Harpaz, R., Markowitz, L.E.. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR. 2017; 66: 1-28 [OpenAIRE] [PubMed] [DOI]

Giuliano, A.R., Lu, B., Nielson, C.M., Flores, R., Papenfuss, M.R., Lee, J.H., Abrahamsen, M., Harris, R.B.. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. JID. 2008; 198: 827-835 [PubMed] [DOI]

Forman, D., de Martel, C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M.. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30: F12-F23 [OpenAIRE] [PubMed] [DOI]

Yanofsky, V.R., Patel, R.V., Goldenberg, G.. Genital warts. A comprehensive review. J. Clin. Aesthet. Dermatol.. 2012; 5: 25-36 [OpenAIRE] [PubMed]

Armstrong, L.R., Preston, E.J.D., Reichert, M., Phillips, D.L., Nisenbaum, R., Todd, N.W., Jacobs, I.N., Inglis, A.F., Manning, S.C., Reeves, W.C.. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin. Infect. Dis.. 2000; 31: 107-109 [PubMed] [DOI]

Chirillă, M., Bolboacă, S.D.. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur. Arch. Otorhinolaryngol.. 2013 [PubMed] [DOI]

Giuliano, A.R., Harris, R., Sedjo, R.L., Baldwin, S., Roe, D., Papenfuss, M.R., Abrahamsen, M., Inserra, P., Olvera, S., Hatch, K.. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The young women’s health study. JID. 2002; 186: 462-469 [PubMed] [DOI]

Charlton, B.M., Reisner, S.L., Agénor, M., Gordon, A.R., Sarda, V., Austin, S.B.. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Health. 2017; 4: 202-209 [OpenAIRE] [PubMed] [DOI]

Raymakers, A.J., Sadatsafavi, M., Marra, F., Marra, C.A.. Economic and humanistic burden of external genital warts. Pharmacoeconomics. 2012; 30: 1-16 [PubMed] [DOI]

Van de Velde, N., Boily, M.C., Drolet, M., Franco, E.L., Mayrand, M.H., Kliewer, E.V., Kliewer, E.V., Coutlée, F., Laprise, J.F., Malagón, T.. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: A model-based analysis. J. Natl. Cancer Inst.. 2012; 104: 1712-1723 [OpenAIRE] [PubMed] [DOI]

Schobert, D., Remy, V., Schoeffski, O.. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ. Rev.. 2012; 2: 19 [OpenAIRE] [PubMed] [DOI]

Héquet, D., Rouzier, R.. Determinants of geographic inequalities in HPV vaccination in the most populated region of France. PLoS ONE. 2017; 12 [OpenAIRE] [PubMed] [DOI]

Fregnani, J.H., Carvalho, A.L., Eluf-Neto, J., Ribeiro, K.d.C.B., Kuil, L.d.M., da Silva, T.A., Rodrigues, S.L., Mauad, E.C., Longatto-Filho, A., Villa, L.L.. A school-based human papillomavirus vaccination program in Barretos, Brazil: Final results of a demonstrative study. PLoS ONE. 2013; 8 [OpenAIRE] [PubMed] [DOI]

Hayashi, Y., Shimizu, Y., Netsu, S., Hanley, S., Konno, R.. High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan. Vaccine. 2012; 30: 5547-5550 [PubMed] [DOI]

53 references, page 1 of 4
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2017

Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance

Oroma Nwanodi; Helen Salisbury; Curtis Bay;